Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Geraldine R. Vink"'
Autor:
Astrid Kramer, Carmen Rubio‐Alarcón, Daan van denBroek, Daan C. L. Vessies, Iris van't Erve, Gerrit A. Meijer, Geraldine R. Vink, Ed Schuuring, Remond J. A. Fijneman, Veerle M. H. Coupé, Valesca P. Retèl
Publikováno v:
Molecular Oncology, Vol 18, Iss 11, Pp 2730-2742 (2024)
Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology, but the road toward implementation in clinical practice is unclear. We aimed to support the implementation process by exploring potential future pathways of ctDN
Externí odkaz:
https://doaj.org/article/4e90fa3c429847ecbf02abb2a149a0e3
Autor:
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, Veerle M. H. Coupé
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating
Externí odkaz:
https://doaj.org/article/df477bb60b4f45289ac535ad731952c5
Autor:
Hidde Swartjes, Seyed M. Qaderi, Steven Teerenstra, Jose A. E. Custers, Marloes A. G. Elferink, Bob J. van Wely, Jacobus W. A. Burger, Wilhelmina M. U. van Grevenstein, Peter van Duijvendijk, Emiel G. G. Verdaasdonk, Marnix A. J. de Roos, Veerle M. H. Coupé, Geraldine R. Vink, Cornelis Verhoef, Johannes H. W. de Wilt
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Colorectal cancer (CRC) is among the most frequently diagnosed cancers. Approximately 20–30% of stage I-III CRC patients develop a recurrent tumour or metastases after curative surgical resection. Post-operative follow-up is ind
Externí odkaz:
https://doaj.org/article/7bdfb6bc83564967aabd6a3acc22b0d9
Autor:
Koen Zwart, Frederieke H. van derBaan, Romain Cohen, Thomas Aparicio, Christelle de laFouchardiére, Thierry Lecomte, Cornelis J. A. Punt, David Sefrioui, Rik J. Verheijden, Geraldine R. Vink, G. Emerens Wensink, Aziz Zaanan, Miriam Koopman, David Tougeron, Jeanine M. L. Roodhart
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15841-15853 (2023)
Abstract Background Current knowledge on prognostic biomarkers (especially BRAFV600E/RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with proficient mismatch repair (pMMR) tumors. It is uncertain whether these b
Externí odkaz:
https://doaj.org/article/78172ed8afd94d10ab4cb901ea49fe41
Autor:
Jeroen W. G. Derksen, Geraldine R. Vink, Marloes A. G. Elferink, Jeanine M. L. Roodhart, Helena M. Verkooijen, Wilhelmina M. U. van Grevenstein, Peter D. Siersema, Anne M. May, Miriam Koopman, The PLCRC Study Group
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serve
Externí odkaz:
https://doaj.org/article/179162c857894da7b1109e3921ce2513
Autor:
Gabrielle Jongeneel, Marjolein J. E. Greuter, Felice N. van Erning, Miriam Koopman, Geraldine R. Vink, Cornelis J. A. Punt, Veerle M. H. Coupé
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: We aimed to evaluate the cost-effectiveness of risk-based strategies to improve the selection of surgically treated stage II colon cancer (CC) patients for adjuvant chemotherapy. Methods: Using the ‘Personalized Adjuvant TreaTment in Ea
Externí odkaz:
https://doaj.org/article/18beb219dd1c48868a951dda264ba498
Autor:
Gabrielle Jongeneel, Marjolein J. E. Greuter, Felice N. van Erning, Miriam Koopman, Geraldine R. Vink, Cornelis J. A. Punt, Veerle M. H. Coupé
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Background: Our aim was to evaluate the cost effectiveness of 3 months’ adjuvant chemotherapy versus 6 months in high-risk (T4 stage + microsatellite stable) stage II colon cancer (CC) patients. Methods: Using the validated PATTERN Markov cohort mo
Externí odkaz:
https://doaj.org/article/21cfc3464d404544b84f5e96f5790773
Autor:
G E Wensink, Karen Bolhuis, Marloes A G Elferink, Remond J A Fijneman, Onno Kranenburg, Inne H M Borel Rinkes, Miriam Koopman, Rutger-Jan Swijnenburg, Geraldine R Vink, Jeroen Hagendoorn, Cornelis J A Punt, Jeanine M L Roodhart, Sjoerd G Elias
Publikováno v:
The British journal of surgery, 110(3), 362-371. John Wiley and Sons Ltd
BackgroundPatients who develop early extrahepatic recurrence (EHR) may not benefit from local treatment of colorectal liver metastases (CRLMs). This study aimed to develop a prediction model for early EHR after local treatment of CRLMs using a nation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f4de938dbebf88c099d8b3676ae39d
https://doi.org/10.1093/bjs/znac461
https://doi.org/10.1093/bjs/znac461
Autor:
Karlijn L. van Rooijen, Jeroen W. G. Derksen, Helena M. Verkooijen, Geraldine R. Vink, Miriam Koopman
Publikováno v:
International Journal of Cancer. 151:1270-1279
The IDEA trial showed no clinical relevant differences in efficacy between 3 and 6 months of oxaliplatin-based adjuvant chemotherapy (ACT) in colon cancer (CC), while toxicity was substantially lower in the 3 months regimen. Therefore, in 2017 the Du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c06ee7ae3c3da84ebedb22cfc7a1cf11
https://doi.org/10.1002/ijc.34149
https://doi.org/10.1002/ijc.34149
Autor:
Patricia A.H. Hamers, Geraldine R. Vink, Marloes A.G. Elferink, Rebecca K. Stellato, Willemieke P.M. Dijksterhuis, Cornelis J.A. Punt, Miriam Koopman, Anne M. May, Laurens V. Beerepoot, Geert-Jan Creemers, Hester van Cruijsen, Jan Willem B. de Groot, Henk K. van Halteren, Helgi H. Helgason, Mathijs P. Hendriks, Ronald Hoekstra, Lieke H. van Huis-Tanja, Ellen Kapiteijn, Maartje Los, Esther van Meerten, Natascha A.J.B. Peters, Johannes F.M. Pruijt, Patricia Quarles van Ufford-Mannesse, Mark P.S. Sie, Dirkje W. Sommeijer, Leontine E.A.M.M. Spierings, Frederiek Terheggen, Manuel L.R. Tjin-A-Ton, Liselot B.J. Valkenburg-van Iersel, Theo van Voorthuizen, Judith de Vos-Geelen, Annelie J.E. Vulink, Agnès J van de Wouw
Publikováno v:
Clinical Colorectal Cancer, 21(2), 154-166. Elsevier
on behalf of the QUALITAS study group 2022, ' Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS) ', Clinical Colorectal Cancer, vol. 21, no. 2, pp. 154-166 . https://doi.org/10.1016/j.clcc.2022.03.002
Clinical colorectal cancer, 21(2), 154-166. Elsevier
Clinical Colorectal Cancer, 21(2), 154-166. CIG Media Group, L.P.
on behalf of the QUALITAS study group 2022, ' Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS) ', Clinical Colorectal Cancer, vol. 21, no. 2, pp. 154-166 . https://doi.org/10.1016/j.clcc.2022.03.002
Clinical colorectal cancer, 21(2), 154-166. Elsevier
Clinical Colorectal Cancer, 21(2), 154-166. CIG Media Group, L.P.
INTRODUCTION: The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients. Unfortunately, quality of life (QoL) was not asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8074c3f95e3d5c5234a7fcca8125ae85
https://doi.org/10.1016/j.clcc.2022.03.002
https://doi.org/10.1016/j.clcc.2022.03.002